On April 3, 2022 Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, reported two poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, including proxalutamide to treat COVID-19 and a c-Myc Degrader to treat blood cancer and small cell lung cancers (SCLC) (Press release, Suzhou Kintor Pharmaceuticals, APR 3, 2022, View Source [SID1234611375]). This year’s AACR (Free AACR Whitepaper) annual meeting will be held in the city of New Orleans, United States, on April 8-13, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

E-Poster
Mechanisms of action (MOA) for proxalutamide, an androgen receptor (AR) antagonist, for the treatment of mild, moderate and severe COVID-19 patients

Abstract#: 5274

Session Title: COVID-19 and Cancer

Session Time: April 8, 2022, 12:00 PM – 1:00 PM

Abstract Link: View Source!/10517/presentation/18533

Discovery and evaluation of GT19630, a c-Myc/GSPT1 cereblon E3 ligase modulator(CELMoD) , for targeting Myc-driven blood cancers and small cell lung cancers(SCLC)

Abstract#: 5479

Session Title: Small Molecule Therapeutic Agents

Session Time: April 8, 2022, 12:00 PM – 1:00 PM

Abstract Link: View Source!/10517/presentation/18624

Please refer to the website of AACR (Free AACR Whitepaper) for more details.